Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
17 Août 2023 - 2:00PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, announced that
its Chief Financial Officer and Head of Corporate Development,
Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a
new professional opportunity as the chief executive officer of a
private biotechnology company. The Company has initiated a search
to identify a suitable replacement for Dr. Al-Wakeel, who will
remain with Kronos Bio until September 15, 2023 to ensure business
continuity.
“During his tenure, Yasir made tremendous contributions to
Kronos Bio,” said Norbert Bischofberger, Ph.D., president and chief
executive officer of Kronos Bio. “He helped us navigate a
successful IPO, built a highly skilled and strategic finance
function and established pivotal partnerships that have bolstered
our capabilities and set us up for continued success. While
we will miss Yasir’s leadership, we wish him all the best as he
continues to advance in his career. We are grateful for his
commitment to a smooth transition over the next month as we
identify his successor.”
“While I am pleased to take the next step in my career as the
CEO of a private biotechnology company, I will miss Norbert and my
colleagues at Kronos Bio, and our shared passion to bring forward
new and innovative therapies for difficult-to-treat cancers,” said
Yasir Al-Wakeel, BM BCh. “I’m proud to have played a role in the
significant strides that Kronos Bio has made over the last few
years progressing its clinical programs and discovery platform. I’m
confident that Kronos Bio is well positioned for success with its
innovative science, near-term data milestones and seasoned
leadership team.”
About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical company that
is advancing two investigational compounds in clinical trials for
patients with cancer. The company is developing its CDK9 inhibitor
KB-0742 as a treatment for MYC-amplified solid tumors and other
transcriptionally addicted solid tumors, and lanraplenib, a
next-generation SYK inhibitor, for patients with FLT3-mutated acute
myeloid leukemia. The company’s scientific focus is on developing
medicines that target the deregulated transcription that is the
hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and
has a research facility in Cambridge, Mass. For more information,
visit www.kronosbio.com or follow the company on LinkedIn.
Contacts for Investors and Media:
Company Contact:Sarah Connors, Vice President
of Investor Relations and Corporate CommunicationsKronos
Bio857-290-7305sconnors@kronosbio.com
Agency Contact:Brendan Strong, Managing
DirectorArgot Partners
212-600-1902kronosbio@argotpartners.com
Kronos Bio (NASDAQ:KRON)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Kronos Bio (NASDAQ:KRON)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024